Our sponsors know that HMP Global Market Access Insights (MAI) conducts a Brand Survey as part of our annual IDN Trend Survey. For 2022, we continued this tradition as we set out to understand the prescribing burden for IDN oncologists, across 10 tumor types and 90 brands.
MAI defines “routine access” as the condition in which a cancer drug is available for ordering through an EMR with no additional work on the doctors’ part beyond selecting a regimen or order set. We queried 138 oncology pharmacists based on our definition of “routine access” to ordering drugs in EHR, defined as:
Low Prescribing Burden: where an Rx order receives routine review or approval. This constitutes “routine access”
Medium Prescribing Burden: where an Rx order is likely to trigger utilization or clinical guideline review with some justification required, although that justification may be automated
High Prescribing Burden: where an Rx order may include a highly restrictive internal approval process, or compliance with a restrictive pathway, and/or an individual review for each patient
An average oncology brand is subjected to low prescribing burden, or “routine access,” for 25% of the providers. The burden placed on a particular brand varied across providers from different institutions.
Conversely, an average brand is subjected to high prescribing burden for 23% of providers. High prescribing burden level is generally consistent across the 10 tumor types queried: NHL is the disease area in which the highest average prescribing burden level is reported, triggered by multiple CAR-T treatments
Given the variety of brands surveyed, some respondents are not familiar with certain brands and the respective access.
For more information on prescribing burden for individual brands, and the clinical controls and strategies employed by IDNs, stay tuned for our sponsor report presentations in May and June.
As always, please reach out with any comments and questions you may have.
All the best...
-- HMP Market Access Insights Team
Welcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.Chris Van Denburg
We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.Lee Blansett
Welcome to the February 2023 edition of our Monthly Insight Series. This month we discuss how community oncology providers are engaging in value-based care.Taylor Crutison, Lee Blansett, Nandini Jha